Clarient provides cancer diagnostic testing, offering cellular assessment and cancer characterization to community pathologists, academic researchers, university hospitals, and biopharmaceutical companies to bring clarity to a complex disease. Our diagnostics and consultative services range from technical laboratory services to professional interpretation to determine what therapies will work best for patients, and continue with follow-up and case monitoring.

EGFR Mutational Analysis
The epidermal growth factor receptor activates an important pathway that leads to cell proliferation, differentiation, migration/motility, adhesion, protection from apoptosis, enhanced survival and gene transcription. A large body of experimental and clinical work supports the view that EGFR is a relevant target for cancer therapy.
Learn more

Clarient's new breast cancer test helps physicians identify the probability of a patient's cancer returning, and assess the need for chemotherapy.
Learn more

KRAS and BRAF Mutations are Predictors to Response to Therapies in Colorectal Cancer
Recent finding in a gene mutation may be able to better predict which patient may respond better to anti-EGFR therapies.
Learn more

New WHO Reclassification of Myeloproliferative Disorders
Recent discoveries provide means to both differentiate myeloproliferative neoplasms and monitor response to therapy.
Learn more